Vascular Biogenics Ltd.’s $28.3 Million Shares Offering

Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal.Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering of 6,901,790 ordinary…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now